

### What is missing for physicians to prescribe a BCI?

Perrine Rose Rose Seguin, Emmanuel Maby, Jérémie Mattout

#### ▶ To cite this version:

Perrine Rose Rose Seguin, Emmanuel Maby, Jérémie Mattout. What is missing for physicians to prescribe a BCI?. 8th Graz BCI Conference 2019, Sep 2023, Graz, Austria. . hal-04095592

HAL Id: hal-04095592

https://hal.science/hal-04095592

Submitted on 11 May 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



<sup>1</sup> CRNL, DYCOG team, CNRS UMR5292, Inserm U1028, Lyon, France


<sup>2</sup> Université Lyon 1, Lyon, France

<sup>3</sup> Université Jean Monnet, Saint-Etienne, France

# WHAT IS MISSING FOR PHYSICIANS TO PRESCRIBE A BCI?

## Introduction

Since the early development of BCI, clinical applications are presented as a major objective. However, despite notable progress, they struggle to enter the clinical routine. Besides technological limits, we notice that most BCI studies involve healthy subjects, and when applied to patients, they are mainly proof-of-concept studies. Recent « replace » or « restore » BCI studies showed noticeable changes in terms of design, to optimize clinical translation. We will highlight some of these pragmatic turns. We will also compare these new strategies with general clinical guidelines and practices to emphasize what is still missing to allow a rehabilitation physician to prescribe a BCI.



## **Conclusion & Perspectives**

e.g: Vansteensel, NEJM, 2016;

Nuyujukian et al., PLOS ONE, 2018

Gathering stakeholders

**Economic environment** 

Move toward cheaper and

polyvalent effectors

A clinician who would like to prescribe a BCI nowadays would face uncertainty at several levels, from the choice of the most adapted BCI for a given patient, to the effects that she/he could expect. For now, the field is not mature enough to ensure optimal BCI prescription. However, methodological changes that would favor the translation, such as user centered designs and longitudinal studies are spreading rapidly. On the other hand, the dominant engineering culture of the development of BCI is still perceptible in the lack of detailed clinical description of the patients, and in the lack of precise comparison with state of the art assistive devices or rehabilitation strategies. These steps are mandatory to realize realistic cost-benefit studies that are missing to allow the refunding of BCI solutions by health insurance. Finally, a strong "pragmatic" ethical frame would be required and should encompass all these aspects.

Assessment of usability early in

the development process

Realistic cost-benefit studies

e.g: Vansteensel, NEJM, 2016;

e.g: ?

Lugo et al., Ann. Phys. Rehabil. Med., 2019









Roadmap

Publish the detailed clinical profile

(behavior + neuro-imaging tools)

(motor impairments, oculomotor, cognitive, etc.)

e.g: Holz, Arch. Phys. Med. Rehab, 2015;

Wolpaw et al, Neurology 2018;

Pels, Clinical Neurophysiology, 2019

Out of the lab

Assessing longitudinal home use

e.g. Claassen, NEJM, 2019

of the art assistive devices or

rehabilitation strategies

**Ethics** 

« Pragmatic » ethical

guidelines

e.g. ?